The results were statistically significant for patients receiving ipilimumab alone or ipilimumab in combination with a gp100 peptide vaccine when compared to those sufferers who received the control therapy of gp100 alone. The total results were published in the New England Journal of Medicine. Positive results from a randomized Phase II study evaluating ipilimumab in conjunction with regular chemotherapy in previously untreated patients with advanced non-little cell lung cancer.Researchers at BioTime’s subsidiaries OncoCyte Company and ReCyte Therapeutics intend to apply this technology in the advancement of innovative medical items for tumor and vascular diseases. With the license contract, BioTime has decided to fund analysis at The Wistar Institute to progress the technology, and BioTime will receive certain privileges to negotiate extra licenses for just about any technologies invented due to the research. ‘It really is rare to locate a gene like SP100 which has such strategic importance in different fields of medication like oncology and stem cell biology,’ stated Michael West, Ph.D., BioTime’s CEO.